The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years. (Q54587549)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years. |
scientific article |
Statements
The achievement of durable complete cytogenetic remission in late chronic and accelerated phase patients with CML treated with Imatinib mesylate predicts for prolonged response at 6 years. (English)
Federica Andreoni
Rocco G Piazza
Anna Franceschino
Lucia Tornaghi
Federica Colnaghi
Gianmarco Corneo
Enrico M Pogliani
14 August 2006
37
2
111-115